Nakagomi, Atsushi
Shoji, Toshihiro
Okada, Sho
Ohno, Yuji
Kobayashi, Yoshio
Article History
Received: 7 February 2017
Revised: 10 March 2017
Accepted: 4 April 2017
First Online: 5 October 2017
Competing interests
: SO received lecture fees from Otsuka Pharmaceutical (Tokyo, Japan), Takeda Pharmaceutical (Osaka, Japan) and MSD (Tokyo, Japan). SO received a research grant from the Daiwa Securities Health Foundation (Tokyo, Japan) and the Kashiwado Memorial Foundation (Chiba, Japan). YK received lecture fees from Daiichi-Sankyo (Tokyo, Japan), Takeda Pharmaceutical (Osaka, Japan), Bayer Yakuhin (Osaka, Japan) and Boehringer Ingelheim (Ingelheim, Germany). YK received research grants from Boehringer Ingelheim (Ingelheim, Germany), Pfizer (New York, USA), Otsuka Pharmaceutical (Tokyo, Japan), Takeda Pharmaceutical (Osaka, Japan), Mitsubishi Tanabe Pharma (Osaka, Japan), Sumitomo Dainippon Pharma (Osaka, Japan), Astellas Pharma (Tokyo, Japan), St Jude Medical (St. Paul, USA), Abbott Vascular Japan (Tokyo, Japan) and Daiichi-Sankyo (Tokyo, Japan). The remaining authors declare no conflict of interest.
Free to read: This content has been made available to all.